Anti-CD3/anti-PSMA T-cell engager (Xilio Therapeutics)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameAnti-CD3/anti-PSMA T-cell engager (Xilio Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-PSMACD3 T-cell engagers
TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXilio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesXilio Therapeutics IncAbbvie Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A